RecruitingPhase 4NCT06751992

Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients

Neurocognitive Function Changes With Once-Daily Extended-Release Tacrolimus (Envarsus XR) Conversion Compared to Twice-Daily Immediate Release Tacrolimus Maintenance Among Older Kidney Transplant Recipients

Sponsor

Massachusetts General Hospital

Enrollment

92 participants

Start Date

Mar 17, 2026

Study Type

INTERVENTIONAL

Conditions

Old Age Kidney Transplant Recipients

Summary

The objective of this randomized controlled study is to assess the neurocognitive outcomes between individuals using immediate-release (IR) tacrolimus (Prograf®) and those who were converted to extended-release tacrolimus (Envarsus XR) among older kidney transplant recipients (KTRs).

Eligibility

Min Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Conversion to extended-release tacrolimus and a drug called Maintenance of immediate-release tacrolimus for people with kidney transplant recipients and old age. The study is currently recruiting participants at 1 location. People eligible for this study include aged 65 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGConversion to extended-release tacrolimus

Conversion from immediate-release tacrolimus (Prograf) to extended-release tacrolimus (Envarsus XR) as a part of the maintenance immunosuppressive treatment

DRUGMaintenance of immediate-release tacrolimus

Continuing immediate-release tacrolimus (Prograf) as a part of the maintenance immunosuppressive treatment